Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C

被引:2
|
作者
Fernández, I
Castellano, G
de Salamanca, RE
Colina, F
de la Cámara, A
Morán, MJ
Muñoz, R
Solís-Herruzo, JA
机构
[1] Hosp Univ 12 Octubre, Serv Med Aparato Digest, Dept Gastroenterol, Unit Study Porphyrias, ES-28041 Madrid, Spain
[2] Hosp Univ 12 Octubre, Dept Pathol, Unit Study Porphyrias, ES-28041 Madrid, Spain
[3] Hosp Univ 12 Octubre, Dept Clin Epidemiol, Unit Study Porphyrias, ES-28041 Madrid, Spain
关键词
chronic hepatitis; HFE gene mutations; iron status;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Porphyria cutanea tarda (PCT) is sometimes associated with hepatitis C virus chronic infection. The aim of this study was to describe the effect of interferon alfa (IFN-alpha) in the treatment of patients with chronic hepatitis C and PCT. Methods: We treated a total of 66 patients with chronic hepatitis C with IFN-alpha 2b (5 MU t.i.w.) for 12 months. Twenty-two of these patients suffered from PCT as well. These patients differed from patients without PCT in that they were men, past history of alcohol abuse and HFE gene mutations were more common and the source of infection was almost always unknown. Results: Sustained virologic response was obtained in 19.7% of the 66 treated patients, 27.3% in the non-PCT group and 4.5% in the PCT group (P < 0.05). This difference could not be ascribed to the difference in sex of patients, history of alcohol abuse, HCV genotype or iron status. Conclusion: Multivariate logistic regression analysis revealed that PCT is independently and significantly associated with non-sustained response to IFNα therapy. In conclusion, patients with chronic hepatitis C and PCT rarely responded to IFNα treatment.
引用
收藏
页码:314 / 319
页数:6
相关论文
共 50 条
  • [21] THERAPY OF PORPHYRIA CUTANEA TARDA
    KALDOR, I
    TOROK, E
    ZANGEL, V
    DOMONKOS, R
    LAZAR, S
    ACTA DERMATO-VENEREOLOGICA, 1967, 47 (01) : 52 - &
  • [22] Therapy of porphyria cutanea tarda
    Köstler, E
    Wollina, U
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (03) : 377 - 383
  • [23] PORPHYRIA CUTANEA TARDA (CHRONIC PORPHYRIA MIXED)
    SIDELL, C
    ERICKSON, G
    ARCHIVES OF DERMATOLOGY, 1956, 74 (05) : 560 - 561
  • [24] Porphyria cutanea tarda and hepatitis G and C virus infection
    Mancini, C
    Griso, D
    Rivanera, D
    Macrì, A
    Casino, C
    Lilli, D
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (07) : 534 - 535
  • [25] Association between hepatitis C virus and porphyria cutanea tarda
    To-Figueras, Jordi
    MOLECULAR GENETICS AND METABOLISM, 2019, 128 (03) : 282 - 287
  • [26] Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C
    Bonkovsky, Herbert L.
    Rudnick, Sean P.
    Ma, Christopher D. D.
    Overbey, Jessica R.
    Wang, Kelly
    Faust, Denise
    Hallberg, Csilla
    Hedstrom, Karli
    Naik, Hetanshi
    Moghe, Akshata
    Anderson, Karl E.
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (06) : 2738 - 2746
  • [27] Is hepatitis C virus important in the pathogenesis of porphyria cutanea tarda
    Hift, RJ
    Kannemeyer, J
    Meissner, PN
    HEPATOLOGY, 1996, 23 (01) : H292 - H292
  • [28] Porphyria cutanea tarda and hepatitis G and C virus infection
    C. Mancini
    D. Griso
    D. Rivanera
    A. Macrì
    C. Casino
    D. Lilli
    European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17 : 534 - 535
  • [29] Hepatitis C virus infection and porphyria cutanea tarda in Australasia
    Salmon, P
    Oakley, A
    Rademaker, M
    Duffill, M
    ARCHIVES OF DERMATOLOGY, 1996, 132 (01) : 91 - 91
  • [30] HEPATITIS-C IN PATIENTS WITH PORPHYRIA-CUTANEA-TARDA
    KOESTER, G
    FELDMAN, J
    BIGLER, C
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 31 (06) : 1054 - 1054